48
Participants
Start Date
January 14, 2020
Primary Completion Date
December 30, 2022
Study Completion Date
December 30, 2022
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3
Single intravenous infusion of ceftazidime-avibactam over 2 hours
Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
Hsinchu Mackay Memorial Hospital, Department of Pharmacy, Hsinchu
Debreceni Egyetem Klinikai Központ, Debrecen
Szabolcs-Szatmár-Bereg Megyei Kórházak és Oktatókórház, Jósa András Oktatókórház, Nyíregyháza
Kanizsai Dorottya Korhaz, Nagykanizsa
National Taiwan University Hospital, Taipei
Tallinn Children's Hospital, Tallinn
Duke University Investigational Drug Services, Durham
Duke University Medical Center, Durham
Hsinchu Mackay Memorial Hospital, Hsinchu
University of Utah, Salt Lake City
Primary Children's Hospital, Salt Lake City
Kasturba Medical College and Hospital, Manipal
Tufts Children's Hospital at Tufts Medical Center, Boston
"Athens General Children's Hospital Panagioti and Aglaias Kyriakou", Athens
"ATTIKON University General Hospital", Chaïdári
"Hippokration General Hospital of Thessaloniki", Thessaloniki
Ospedale Pediatrico Bambino Gesu, Rome
Univerzitna nemocnica Martin, Martin